open access

Vol 12, No 2 (2009)
Reviews
Published online: 2010-03-12
Submitted: 2012-01-23
Get Citation

The role of radiopharmaceuticals in diagnosis of melanoma malignum

Michał Janczak
Nucl. Med. Rev 2009;12(2):83-88.

open access

Vol 12, No 2 (2009)
Reviews
Published online: 2010-03-12
Submitted: 2012-01-23

Abstract

Melanoma malignum belongs to the group of neoplasms with the highest lethality. Due to the continuous increase of incidence in numerous countries, this malignance has become a serious health problem.
This highly aggressive neoplasm is a source of metastases to most organs and eo ipso of bad prognosis. Early detection of the primary tumour and of metastases creates a chance for optimal therapy.
The methods of nuclear medicine are becoming more popular in diagnostics of melanomas because they offer advantages over traditional methods of anatomic imaging. Functional imaging, based on the use of modern radiopharmaceuticals frequently offers more successful identification and characterization of malignant neoplasms.
Over the last few decades there have been numerous attempts to utilize, in the diagnostics of melanomas, a number of compounds labelled with radioactive nuclides.
An accepted role in diagnosis of melanoma found a technique of lymphoscintigraphic mapping of lymphatic nodes and of detection of the sentinel node. In addition, modern positron emission tomography (PET) with use of 18F-fluorodeoxyglucose has found acceptance in melanoma diagnostics.
The present review refers to information on the presently used and potential new radiopharmaceuticals promising effective melanoma diagnostics.

Abstract

Melanoma malignum belongs to the group of neoplasms with the highest lethality. Due to the continuous increase of incidence in numerous countries, this malignance has become a serious health problem.
This highly aggressive neoplasm is a source of metastases to most organs and eo ipso of bad prognosis. Early detection of the primary tumour and of metastases creates a chance for optimal therapy.
The methods of nuclear medicine are becoming more popular in diagnostics of melanomas because they offer advantages over traditional methods of anatomic imaging. Functional imaging, based on the use of modern radiopharmaceuticals frequently offers more successful identification and characterization of malignant neoplasms.
Over the last few decades there have been numerous attempts to utilize, in the diagnostics of melanomas, a number of compounds labelled with radioactive nuclides.
An accepted role in diagnosis of melanoma found a technique of lymphoscintigraphic mapping of lymphatic nodes and of detection of the sentinel node. In addition, modern positron emission tomography (PET) with use of 18F-fluorodeoxyglucose has found acceptance in melanoma diagnostics.
The present review refers to information on the presently used and potential new radiopharmaceuticals promising effective melanoma diagnostics.
Get Citation

Keywords

melanoma imaging; radiopharmaceuticals

About this article
Title

The role of radiopharmaceuticals in diagnosis of melanoma malignum

Journal

Nuclear Medicine Review

Issue

Vol 12, No 2 (2009)

Pages

83-88

Published online

2010-03-12

Bibliographic record

Nucl. Med. Rev 2009;12(2):83-88.

Keywords

melanoma imaging
radiopharmaceuticals

Authors

Michał Janczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl